JP2023165983A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023165983A5 JP2023165983A5 JP2023169604A JP2023169604A JP2023165983A5 JP 2023165983 A5 JP2023165983 A5 JP 2023165983A5 JP 2023169604 A JP2023169604 A JP 2023169604A JP 2023169604 A JP2023169604 A JP 2023169604A JP 2023165983 A5 JP2023165983 A5 JP 2023165983A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- antigen
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862678890P | 2018-05-31 | 2018-05-31 | |
| US62/678,890 | 2018-05-31 | ||
| PCT/US2019/034708 WO2019232246A1 (en) | 2018-05-31 | 2019-05-30 | Therapeutic antibodies binding to biantennary lewis b and lewis y antigens |
| JP2020566286A JP7360401B2 (ja) | 2018-05-31 | 2019-05-30 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566286A Division JP7360401B2 (ja) | 2018-05-31 | 2019-05-30 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023165983A JP2023165983A (ja) | 2023-11-17 |
| JP2023165983A5 true JP2023165983A5 (enExample) | 2023-12-18 |
| JP7696404B2 JP7696404B2 (ja) | 2025-06-20 |
Family
ID=66952044
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566286A Active JP7360401B2 (ja) | 2018-05-31 | 2019-05-30 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
| JP2023169604A Active JP7696404B2 (ja) | 2018-05-31 | 2023-09-29 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020566286A Active JP7360401B2 (ja) | 2018-05-31 | 2019-05-30 | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11440967B2 (enExample) |
| EP (1) | EP3802604A1 (enExample) |
| JP (2) | JP7360401B2 (enExample) |
| KR (1) | KR102480815B1 (enExample) |
| CN (1) | CN112533948B (enExample) |
| AU (1) | AU2019278875A1 (enExample) |
| BR (1) | BR112020023380A2 (enExample) |
| CA (1) | CA3106380A1 (enExample) |
| IL (1) | IL279109B2 (enExample) |
| MX (1) | MX2020011385A (enExample) |
| SG (1) | SG11202010025YA (enExample) |
| TW (1) | TWI842712B (enExample) |
| WO (1) | WO2019232246A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7360401B2 (ja) * | 2018-05-31 | 2023-10-12 | グリコネックス インコーポレイテッド | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
| CN120025447A (zh) * | 2023-11-23 | 2025-05-23 | 广东菲鹏制药股份有限公司 | 抗人pvrig抗体及其应用 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237224A (en) | 1974-11-04 | 1980-12-02 | Board Of Trustees Of The Leland Stanford Jr. University | Process for producing biologically functional molecular chimeras |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| IL94872A (en) | 1989-06-30 | 1995-03-30 | Oncogen | Monoclonal or chimeric antibodies reactive with human carcinomas, recombinant proteins comprising their antigen binding region, pharmaceutical compositions and kits comprising said antibodies and methods for imaging human carcinoma using same |
| US5151510A (en) | 1990-04-20 | 1992-09-29 | Applied Biosystems, Inc. | Method of synethesizing sulfurized oligonucleotide analogs |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
| JPH0693A (ja) * | 1992-04-23 | 1994-01-11 | Otsuka Pharmaceut Co Ltd | モノクローナル抗体 |
| US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
| US5792456A (en) | 1994-08-04 | 1998-08-11 | Bristol-Myers Squibb Company | Mutant BR96 antibodies reactive with human carcinomas |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| US6323039B1 (en) | 1999-06-22 | 2001-11-27 | Mitokor | Compositions and methods for assaying subcellular conditions and processes using energy transfer |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| GB0111628D0 (en) | 2001-05-11 | 2001-07-04 | Scancell Ltd | Binding member |
| DE602004030700D1 (de) | 2003-09-24 | 2011-02-03 | Kyowa Hakko Kirin Co Ltd | Rekombinanter antikörper gegen humanen insulin-like growth factor |
| JP5362563B2 (ja) * | 2006-08-03 | 2013-12-11 | アストラゼネカ・アクチエボラーグ | αＶβ６に対する抗体およびその使用 |
| WO2008034181A1 (en) | 2006-09-20 | 2008-03-27 | Arana Therapeutics Limited | ANTI-CANCER ANTIBODIES AGAINST LEWISy AND LEWISb ANTIGENS |
| CN101578296A (zh) * | 2006-11-15 | 2009-11-11 | 梅达雷克斯公司 | 结合btla的人类单克隆抗体及使用方法 |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| CN103261222B (zh) | 2010-09-10 | 2017-07-28 | 医疗免疫有限公司 | 抗体衍生物 |
| WO2013025779A1 (en) | 2011-08-15 | 2013-02-21 | Amplimmune, Inc. | Anti-b7-h4 antibodies and their uses |
| CA2894689A1 (en) | 2012-12-19 | 2014-06-26 | Amplimmune, Inc. | Anti-human b7-h4 antibodies and their uses |
| JP6943760B2 (ja) | 2014-09-12 | 2021-10-06 | ジェネンテック， インコーポレイテッド | 抗ｂ７−ｈ４抗体及び免疫複合体 |
| JP2017531427A (ja) | 2014-10-03 | 2017-10-26 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | グルココルチコイド誘導腫瘍壊死因子受容体（ｇｉｔｒ）抗体およびその使用法 |
| EP4129320A1 (en) | 2015-02-19 | 2023-02-08 | Compugen Ltd. | Anti-pvrig antibodies and methods of use |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| JP7360401B2 (ja) * | 2018-05-31 | 2023-10-12 | グリコネックス インコーポレイテッド | バイアンテナ型ルイスｂおよびルイスｙ抗原に結合する治療抗体 |
-
2019
- 2019-05-30 JP JP2020566286A patent/JP7360401B2/ja active Active
- 2019-05-30 AU AU2019278875A patent/AU2019278875A1/en active Pending
- 2019-05-30 IL IL279109A patent/IL279109B2/en unknown
- 2019-05-30 WO PCT/US2019/034708 patent/WO2019232246A1/en not_active Ceased
- 2019-05-30 CA CA3106380A patent/CA3106380A1/en active Pending
- 2019-05-30 SG SG11202010025YA patent/SG11202010025YA/en unknown
- 2019-05-30 BR BR112020023380-3A patent/BR112020023380A2/pt unknown
- 2019-05-30 KR KR1020207035837A patent/KR102480815B1/ko active Active
- 2019-05-30 US US16/427,146 patent/US11440967B2/en active Active
- 2019-05-30 CN CN201980036582.XA patent/CN112533948B/zh active Active
- 2019-05-30 EP EP19731849.6A patent/EP3802604A1/en active Pending
- 2019-05-30 MX MX2020011385A patent/MX2020011385A/es unknown
- 2019-05-31 TW TW108119035A patent/TWI842712B/zh active
-
2022
- 2022-07-26 US US17/815,117 patent/US11643471B2/en active Active
-
2023
- 2023-02-28 US US18/175,905 patent/US20240067746A1/en active Pending
- 2023-09-29 JP JP2023169604A patent/JP7696404B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| King et al. | Improved tumor targeting with chemically cross-linked recombinant antibody fragments | |
| US12180296B2 (en) | Cross species single domain antibodies targeting mesothelin for treating solid tumors | |
| US10479839B2 (en) | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ | |
| CN105026429B (zh) | 间皮素结构域-特异性单克隆抗体及其用途 | |
| US10548987B2 (en) | Antibody-drug conjugates for targeting CD56-positive tumors | |
| JP2023165983A5 (enExample) | ||
| CA2996205A1 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use | |
| US12122843B2 (en) | High affinity monoclonal antibodies targeting glypican-1 and methods of use | |
| CN102770456A (zh) | 多特异性抗体、抗体类似物、组合物和方法 | |
| US10132799B2 (en) | Screening of conjugated antibodies | |
| WO2016022939A1 (en) | Human monoclonal antibodies specific for 5t4 and methods of their use | |
| WO2023207475A1 (zh) | 靶向gpc3的单克隆抗体和包含此抗体的抗体药物缀合物 | |
| CA3066953A1 (en) | Human monoclonal antibodies specific for cd33 and methods of their use | |
| AU763162B2 (en) | Diagnostic and therapeutic use of antibodies against the urokinase receptor | |
| US20240218055A1 (en) | Lassa virus-specific nanobodies and methods of their use | |
| CN119505001B (zh) | 靶向cd22的全人源抗体及其应用 | |
| JPWO2019232246A5 (enExample) | ||
| CN118234750A (zh) | 抗cd33抗体和其用途 | |
| RU2020141986A (ru) | Терапевтические антитела, связывающиеся с биантеннарными антигенами льюиса b и льюиса y | |
| AU2023451019A1 (en) | Antibody targeting itga2, antibody drug conjugate thereof, and use | |
| WO2021141996A1 (en) | Single- and multi-chain polypeptides that bind specifically to cd3 epsilon | |
| WO2025151746A1 (en) | Methods and compositions for the treatment of pou2f3-driven cancer | |
| Hamblett | Optimization of pretargeted radioimmunotherapy | |
| CN101277977A (zh) | 癌性疾病调节抗体 | |
| Welt | Antibodies in the Therapy of Liver Tumors |